However, before moving into the clinic, further pre-clinical work is needed to better clarify if IL-34-mediated cancer resistance to therapies is either a general phenomenon occurring in all the patients who do not respond to such treatments or restricted to specific subsets of cancers/patients. This evidence concerns the gene IL34 and cancer.